S100A7 and psoriasis: Bimekizumab treatment completely reversed the levels of cytokines/chemokines, anti‐microbial peptides, or proliferation‐related molecules, such as CXCL8, CCL20, IL‐17A, IL‐17F, IL‐17C, keratin 16, IL‐36γ, DEFB4, or S100A7, in psoriasis lesional skin to the levels of non‐lesional skin.13